Patients with IgA nephropathy exhibit high systemic PDGF-DD levels

Nephrology Dialysis Transplantation

Volumn 24, Issue 9, 2009, Pages 2755-2762

  Boor, Peter ^a,b   Eitner, Frank ^a   Cohen, Clemens D ^c   Lindenmeyer, Maja T ^c   Mertens, Peter R ^a,d   Ostendorf, Tammo ^a   Floege, Jürgen ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b SLOVAK MEDICAL UNIVERSITY   (Slovakia)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Glomerulonephritis; Growth factor; Serum marker

Indexed keywords

MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR D; PLATELET DERIVED GROWTH FACTOR DD; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOCAL GLOMERULOSCLEROSIS; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEINURIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULONEPHRITIS, IGA; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PLATELET-DERIVED GROWTH FACTOR; PROTEINURIA; RNA, MESSENGER; VASCULITIS; YOUNG ADULT;

EID: 69249123225     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp152     Document Type: Article

References (21)

1. Floege J, Eitner F, Alpers CE. A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol 2008; 19: 12-23
2. Ostendorf T, van Roeyen CR, Peterson JD et al. A fully human monoclonal antibody (CR002) identifies PDGF-D as a novel mediator of mesangioproliferative glomerulonephritis. J Am Soc Nephrol 2003; 14: 2237-2247
3. Hudkins KL, Gilbertson DG, Carling M et al. Exogenous PDGF-D is a potent mesangial cell mitogen and causes a severe mesangial proliferative glomerulopathy. J Am Soc Nephrol 2004; 15: 286-298
4. Ostendorf T, Rong S, Boor P et al. Antagonism of PDGF-D by human antibody CR002 prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol 2006; 17: 1054-1062
5. LaRochelle WJ, Jeffers M, McDonald WF et al. PDGF-D, a new protease-activated growth factor. Nat Cell Biol 2001; 3: 517-521
6. LaRochelle WJ, Jeffers M, Corvalan JR et al. Platelet-derived growth factor D: tumorigenicity in mice and dysregulated expression in human cancer. Cancer Res 2002; 62: 2468-2473
7. Cohen CD, Frach K, SchlondorffD et al.Quantitative gene expression analysis in renal biopsies: a novel protocol for a high-throughput multicenter application. Kidney Int 2002; 61: 133-140
8. Rong ZH,Wang C, Hao J et al. Expression and clinical implication of platelet-derived growth factor-D and platelet-derived growth factorbeta in childhood IgA nephropathy. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2008; 20: 275-278
9. Cianciolo G, Stefoni S, Zanchelli F et al. PDGF-AB release during and after haemodialysis procedure. Nephrol Dial Transplant 1999; 14: 2413-2419
10. De Marchi S, Cecchin E, Falleti E et al. Long-term effects of erythropoietin therapy on fistula stenosis and plasma concentrations of PDGF and MCP-1 in hemodialysis patients. J Am Soc Nephrol 1997; 8: 1147-1156
11. Rossi E, Casali B, Regolisti G et al. Increased plasma levels of platelet-derived growth factor (PDGF-BB + PDGF-AB) in patients with never-treated mild essential hypertension. Am J Hypertens 1998; 11: 1239-1243
12. Pohlers D, Huber R, Ukena B et al. Expression of platelet-derived growth factors C and D in the synovial membrane of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum 2006; 54: 788- 794
13. Wagsater D, Zhu C, Bjorck HM et al. Effects of PDGF-C and PDGF-D on monocyte migration and MMP-2 and MMP-9 expression. Atherosclerosis 2009; 202: 415-423
14. Bergsten E, Uutela M, Li X et al. PDGF-D is a specific, proteaseactivated ligand for the PDGF beta-receptor. Nat Cell Biol 2001; 3: 512-516
15. Taneda S, Hudkins KL, Topouzis S et al. Obstructive uropathy in mice and humans: potential role for PDGF-D in the progression of tubulointerstitial injury. J Am Soc Nephrol 2003; 14: 2544-2555
16. Changsirikulchai S, Hudkins KL, Goodpaster TA et al. Plateletderived growth factor-D expression in developing and mature human kidneys. Kidney Int 2002; 62: 2043-2054
17. LiuG,Changsirikulchai S, HudkinsKLet al. Identification of plateletderived growth factor D in human chronic allograft nephropathy. Hum Pathol 2008; 39: 393-402
18. Daynes RA, Dowell T, Araneo BA. Platelet-derived growth factor is a potent biologic response modifier of T cells. J ExpMed 1991; 174: 1323-1333
19. Appel S, Boehmler AM, Grunebach F et al. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood 2004; 103: 538- 544
20. Zoja C, Corna D, Rottoli D et al. Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. Kidney Int 2006; 70: 97-103
21. Hawthorne T, Giot L, Blake L et al. A phase I study of CR002, a fullyhuman monoclonal antibody against platelet-derived growth factor-D. Int J Clin Pharmacol Ther 2008; 46: 236-244